U.S. FDA Approves INVOKANA ® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD

INVOKANA ® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKDApproval is based on the landmark Phase 3 CREDENCE renal outcomes study – the only completed renal out comes study of a diabetes medicine
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news